Specific cancer risks vary by the gene concerned; mutations in MLH1, MSH2 and EPCAM result in similarly higher risks for CRC (~50% lifetime risk) and endometrial cancer (~50% lifetime risk) (12). Here, MSH2 is linked to cancer.